GBM radiosensitizers: dead in the water…or just the beginning?

Bindra, R. S., Chalmers, A. J. , Evans, S. and Dewhirst, M. (2017) GBM radiosensitizers: dead in the water…or just the beginning? Journal of Neuro-Oncology, 134(3), pp. 513-521. (doi: 10.1007/s11060-017-2427-7) (PMID:28762004)

145807.pdf - Accepted Version



The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control. Unfortunately, decades of clinical trials testing a wide range of novel therapeutic approaches have failed to yield any clinically viable radiosensitizers. However, many of  the previous radiosensitizing strategies were not based on clear pre-clinical evidence, and in many cases blood-barrier penetration was not considered. Furthermore, DNA repair inhibitors have only recenly arrived in the clinic, and likely represent potent agents for glioma radiosensitization. Here, we present recent progress in the use of small molecule DNA damage response inhibitors as GBM radiosensitizers. In addition, we discuss the latest progress in targeting hypoxia and oxidative stress for GBM radiosensitization.

Item Type:Articles
Keywords:DNA damage response, DNA repair, hypoxia, radiosensitizer.
Glasgow Author(s) Enlighten ID:Chalmers, Professor Anthony
Authors: Bindra, R. S., Chalmers, A. J., Evans, S., and Dewhirst, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Journal of Neuro-Oncology
ISSN (Online):1573-7373
Published Online:31 July 2017
Copyright Holders:Copyright © 2017 Springer Science+Business Media
First Published:First published in Journal of Neuro-Oncology 134(3): 513-521
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record